FDA reports possible association between breast implants, ALCL

January 01, 2016

An epidemiological study reviewed evidence from five long-term studies of 43,000 women with breast implants and followed for up to 37 years and noted no difference in the incidence ratio of non-Hodgkin's lymphoma in implant patients (Lipworth, March 2009).A Scandinavian cancer incidence study evaluated 6,222 women with breast implants including 3,336 women with 15 or more years of follow-up and 827 with 25 or more years of follow-up and found no excess of lymphoma in subjects with implants (Lipworth, Jan 2009).A large, controlled Canadian cancer study followed 24,558 breast augmentation patients and 15,893 women who received other cosmetic surgeries and found a similar incidence of non-Hodgkin's lymphoma after over 600,000 person years of follow-up (Brisson, 2006).

The incidence of primary ALCL in the breast of U.S. females is approximately 1.2 per year. The FDA is doing its due diligence to define any possible relationship it has with breast implants or possible scar tissue around implants.  Due to the low numbers of total cases in the world at this time, it is difficult to make any definitive correlations.  However, awareness of breast cancer in general hopefully will increase women's desire for routine care and follow-up.  This alone may be a good thing if it promotes early recognition and patient's awareness of any type of breast cancer regardless if women have implants or not.  The AACS recommends that women perform routine breast self-examinations whether they have implants or not as an important diagnostic tool.  This, along with routine physician exams and appropriate imaging such as ultrasound, mammogram or MRI when indicated, will promote early recognition of any type of breast cancer. The AACS will do our part to keep surgeons and the public up to date with new developments on the ALCL issue or other safety issues regarding cosmetic surgery.

SOURCE American Academy of Cosmetic Surgery